Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460031 · ClinicalTrials.gov registry record · Phase 2
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00460031 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT00460031, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving ketoconazole and hydrocortisone together with lenalidomide may be an effective treatment for prostate cancer. PURPOSE: This phase II trial is studying how well giving ketoconazole and hydrocortisone together with lenalidomide works in treating patients with prostate cancer that did not respond to hormone therapy.
Interventions
- DRUG lenalidomide
- DRUG ketoconazole
- DRUG therapeutic hydrocortisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-09-01 |
| Est. Completion | 2010-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460031
The ClinicalTrials.gov registry entry for NCT00460031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lenalidomide is the first listed.
NCT00460031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460031 about?
NCT00460031 is a clinical study titled "Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving ketoconazole and hydrocortisone together with lenalidomi...
What is the current status of trial NCT00460031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2006-09-01. Estimated completion is 2010-08-31.
What interventions are being tested in trial NCT00460031?
The interventions under investigation include: lenalidomide (DRUG), ketoconazole (DRUG), therapeutic hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT00460031?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.